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Background: The impact of extended use of ART in developing countries has been enormous. A thorough
understanding of all factors contributing to the success of antiretroviral therapy is required. The current study aims to
investigate the value of cross-sectional drug resistance monitoring using DNA and RNA oligonucleotide ligation assays
(OLA) in treatment cohorts in low-resource settings. The study was conducted in the first cohort of children gaining
access to structured ART in Peru.
Methods: Between 2002–5, 46 eligible children started the standard regimen of AZT, 3TC and NFV Patients had a
median age of 5.6 years (range: 0.7-14y), a median viral load of 1.7·105 RNA/ml (range: 2.1·103 – 1.2·106), and a median
CD4-count of 232 cells/μL (range: 1–1591). Of these, 20 patients were classified as CDC clinical category C and 31/46 as
CDC immune category 3. At the time of cross-sectional analysis in 2005, adherence questionnaires were administered.
DNA OLAs and RNA OLAs were performed from frozen PBMC and plasma, RNA genotyping from dried blood spots.
Results: During the first year of ART, 44% of children experienced virologic failure, with an additional 9% failing by the
end of the second year. Virologic failure was significantly associated with the number of resistance mutations detected by
DNA-OLA (p < 0.001) during cross-sectional analysis, but also with low immunologic CDC-scores at baseline (p < 0.001).
Children who had been exposed to unsupervised short-term antiretrovirals before starting structured ART showed
significantly higher numbers of resistance mutations by DNA-OLA (p = 0.01). Detection of M184V (3TC resistance) by
RNA-OLA and DNA-OLA demonstrated a sensitivity of 0.93 and 0.86 and specificity of 0.67 and 0.7, respectively, for the
identification of virologic failure. The RT mutations N88D and L90M (NFV resistance) detected by DNA-OLA correlated
with virologic failure, whereas mutations at RT position 215 (AZT resistance) were not associated with virologic failure.
Conclusions: Advanced immunosuppression at baseline and previous exposures to unsupervised brief cycles of ART
significantly impaired treatment outcomes at a time when structured ART was finally introduced in his cohort. Brief
maternal exposures to with AZT +/− NVP for the prevention of mother-to-child transmission did not affect treatment
outcomes in this group of children. DNA-OLA from frozen PBMC provided a highly specific tool to detect archived drug
resistance. RNA consensus genotyping from dried blood spots and RNA-OLA from plasma consistently detected drug
resistance mutations, but merely in association with virologic failure.* Correspondence: barbara.rath@gmail.com
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Antiretroviral therapy (ART) has, for the past years,
increased the hope for survival of millions of people living
with the human immunodeficiency virus (HIV) world-
wide, adults as well as children. A clear survival advantage
was achieved for HIV-infected patients with a dramatic
decrease in new AIDS cases [1]. Immune reconstitution
ensues when viral replication can be suppressed success-
fully over time [2].
Once a first-line regimen has failed however, the rea-
sons for such failure may be complex, including malnutri-
tion and co-morbidities leading to poor absorption of
medications. Lack of economic resources and education
may further complicate the already difficult adherence to
complex medication schedules [3-11]. Some patients may
have been pre-exposed to intermittent or erratic courses
of antiretrovirals through aid programs, private activities
and contacts abroad. HIV-infected children may have
also been infected with a resistant maternal virus through
mother-to-child transmission (MTCT) [12,13]. In resource-
limited settings where medications for standard first-line
ART medications are often purchased en bloc and large
groups of patients are started on ART simultaneously,
cross-sectional drug resistance testing may be particularly
useful.
This study aims to test the value and feasibility of
cross-sectional resistance testing as well as innovative
tools to display disease progression or clinical/immuno-
logical improvement in the first cohort of children star-
ting ART in Peru. With Global Fund support, structured
ART first became available in August 2002 to a select
group of HIV-infected children at the Instituto Nacional
de Salud del Niño (INSN) in Lima, based on the criteria
established by the Guideline for the Management of the
HIV-Infected Child by the Peruvian Ministry of Health
(MINSA) [14-17].
In contrast to a neonatal cohort starting ART several
years later, the majority of patients in this first cohort at
the INSN were school-age, had already progressed to
AIDS when starting ART and were born before the broad
introduction of prevention of mother-to-child transmi-
ssion (pMTCT) programs in Peru [18]. Therefore, most
patients were considered ART-naive prior to starting the
Peruvian standard first-line regimen, consisting azidothy-
midine (AZT, 100 mg/m2 every 12 hours) with lamivudine
(3TC, 4 mg/Kg. every 12 hours) and nelfinavir (NFV,
25 mg/Kg. every 8 hours) [17].
At the time of introduction of ART in Peru, access to
drug resistance testing was still limited. To save cost, alter-
native testing methodologies and transportation moda-
lities were sought, such as the Oligonucleotide Ligation
Assay (OLA) [19-21] and filter cards for the transporta-
tion of blood samples as dried spots [22-26].
The aims of the study were:1. To determine the prevalence of antiretroviral drug
resistance in children with virologic failure versus no
virologic failure.
2. To evaluate the sensitivity of the DNA-OLA from
frozen peripheral blood mononuclear cells (PBMC) as
compared to the OLA from virion RNA (plasma) and
RNA consensus sequencing from dried blood spots.
3. To determine factors associated with virologic failure
and drug resistance development.
4. To design a simple and integrative display of clinical/
immunological progression of HIV disease after ART
initiation.Methods
Patient Population and Study Procedures
From 2002–2005, study participants had undergone stand-
ard medical procedures and routine HIV medical care at
the Infectious Diseases Service at the INSN. According to
the MINSA Guideline for the Management of the HIV-
Infected Children, CD4+counts had been determined every
3 months, and viral load every 6 months at the Peruvian
National Institutes of Health (Instituto Nacional del Salud,
INS) [16]. Antiretroviral therapy for eligible patients was
provided free of charge by the MINSA. Eligibility criteria
for ART provided by the Peruvian Ministry of Health
included: Established perinatal HIV infectiona and age <
18 months, or age >18 months and CDC immune category
2 or 3. Exceptions were planned for asymptomatic patients
with a rapid decline in CD4+ or viral load >100,000cp/ml
(or >10,000-20,000 in those > 30 months) [16]. Ethics ap-
proval was obtained by the respective institutional review
boards (IRB) in the US and Peru.
For the cross-sectional analysis in 2005, all eligible sub-
jects undergoing ART according to the MINSA program
who agreed to participate and whose parents/guardians
had signed the informed consent, were included. Basic cli-
nical and virologic parameters from the start of ART in the
individual patient until the date of testing were extracted
from routine medical records and laboratory reports (viral
load and CD4 testing data). Additional parameters were
obtained, such as CDC stage [27], opportunistic and other
infections, medication and dosing information, and adverse
events attributable to ART. A previously published standar-
dized adherence questionnaire (PACTG P1042S) was used
at the time of cross-sectional analysis to systematically
measure adherence based on information provided by pa-
rents and caregivers [28,29].
At the time of the first regular follow-up visit after entry
into the study, routine blood sampling was again per-
formed at the INS. In addition, 5 ml of citrated blood were
collected from study participants for resistance testing. In
addition, two Guthrie filter cards were collected with 4 ca-
pillary blood spots (finger prick) of 50 uL each.
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
Rath et al. BMC Infectious Diseases 2013, 13:1 Page 3 of 12
http://www.biomedcentral.com/1471-2334/13/1Virologic testing
Ficoll-Hypaque centrifugation and separation of the
citrated blood was performed at the PRISMA laboratory
in Lima. Plasma and PBMC were immediately stored se-
parately at -20C and shipped on dry ice to the Tulane and
LSU PACTU laboratory for RNA and DNA extraction.
Viral loads in plasma were quantified by real-time RT-
PCR as described [30].
The OLA was conducted according to the NIH protocol
for mutations at HIV-1B protease positions D30N, I50V,
V82A, V82S, V82T, I84V, N88D, and L90M as well as re-
verse transcriptase positions K103N, Y181C, K65R, T215F,
T215Y, M184V, and Q151M [21,31]. Dried Blood Spots
(DBS) collected on Guthrie cards were stored at room
temperature to be shipped to the Stanford Center for
AIDS Research for consensus RNA sequencing [32].
Definition of virologic failure
For the purposes of the study, virologic failure was
defined by two or more consecutive HIV RNA measure-
ments above the detection limit (400cp/ml), 4 –
6 months after the initiation of ART therapy in patients
where ≥ 2 viral load measurements were available. In
patients P016T, P021T, P041T, P053T and P057T only
two viral load measurements were available in total.
These patients all showed signs of virologic failure indi-
cated by HIV RNA measurements > 400cp/ml >
10 months after treatment initiation.
Sample size calculation
We assessed the population size N needed for assessing
differences in resistance development between patients
failing ART and those successfully treated.
We assumed that 50% of patients would eventually
fail ART P (failure) = 0.5 and that those failing ART
would with 90% probability develop drug resistance P
(res. |failure) = 0.9.
Conversely, successfully treated patients may with 10%
probability develop resistance P (res.|sucess) = 0.1. We
can therefore compute the expected number of patients
with failure and resistance a = P(res. |failure)●P(failure)●N,
with failure and no resistance b = (1-P(res. |failure))●P
(failure)●N, with no failure and resistance c = P(res. |
success)●(1-P (failure))●N and with no failure and no
resistance d = (1-P(res. |success))●1-P(failure))●N.
According to Fisher’s exact statistics p ¼
aþ b
a
 
cþ d
c
 
N
aþ c
 
for the underlying contingency table, we could show signifi-
cance at the 5% level (p ≤ 0.05) for a sample size of N = 12.
For values P(res. |failure) = 0.8, P(res. |failure) =0.7 and
P(res. |failure) = (1-P(res. |sucess)) population sizes of N =
12 and N = 22 would be required.Rates of clinical/immunological progression
For the purpose of this analysis, CDC categories were ap-
plied in a novel way, assigning new CDC categories at each
assessment time point ignoring previous CDC scores.
The rates of clinical and immunological progression rC
and rI respectively (average change of CDC score per
year throughout the study population) were computed
with the following formula
rI
rC
 
¼
X
mI
Fm;I
ÄnmI
X
mC
Fm;C
ÄnmC
0
BBB@
1
CCCA , where mI and mC denote
the magnitude (number of scores) of change observed and
Fm,I and Fm,C the fractions that have changed by that mag-
nitude within a certain time interval. For our evaluation,
we computed the rates of immunological and clinical pro-
gressionfrom enrolment throughout years 1, 2 and and
beyond (>=3).
Assessment of the nutritional status using standard
scores (Z-scores)
Malnutrition in the study population was assessed in
terms of standard scores (z-scores) of child weight at en-
rolment in relation to the WHO reference weight [33].
The standard scores are defined by z ¼ xμσ , where x
represents the child’s weight and μ and σ denote the aver-
age weight within the child’s age category based on the
WHO reference and standard deviation, respectively [33].
A standard score of z = −2 therefore denotes that the
child’s weight is two standard deviations below average
(i.e. x = μ-2σ).
Results
Demographics
A total number of 46 children were enrolled between
September 2002 and March 2005. Median age at enrol-
ment was 5.6 years (range: 0.7-14y). The median viral load
at enrolment was 1.7∙105 RNA/ml (range: 2.1∙103 – 1.2∙106)
and the median CD4-count was 232 cells/μL (range: 1–
1591). Notably, five children had CD4 counts below 10
cells/μL. The median weight at enrolment was 18 kg
(range: 5.5-45). Notably, 43/46 (93%) had negative z-scores
for child weight compared to the WHO reference corre-
sponding age group [33], indicating evidence of malnutri-
tion in this cohort. The median z-score was −2 (range:
-4 to 0). CDC clinical categories (according to the 1994
Revised Classification System for HIV Infection in Chil-
dren [27]) were attributed to each patient at baseline and
again with each follow-up visit. Seven children were classi-
fied as clinical category N (not symptomatic), 4 children
fell into clinical category A (mildly symptomatic), 15 were
in category B (moderately symptomatic) and 20 were in
category C (severely symptomatic). Notably, eight children
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http://www.biomedcentral.com/1471-2334/13/1(17%) were co-infected with active tuberculosis at enrol-
ment. Children were also staged with respect to immune
categories, according to the 1994 CDC classification system
[27]. Four children were in category 1, 11 were in category
2, and 31 fell into category 3. Basic demographic charac-
teristics are displayed in Table 1.
Vertical HIV transmission was the mode of infection
for all but two children, who were infected by blood
transfusion. Seven mothers had received antiretroviral
prophylaxis with AZT +/− NVP for the prevention of
mother-to-child transmission (pMTCT). Three children
had been exposed to postnatal AZT for pMTCT (P019T,
P020T, P028T). Four children had been exposed to un-
supervised ART prior to enrolment: two children
(P057T, P067T) received 3TC+AZT prior to enrolment.
One child (P067T) continued NFV+3TC+AZT without
any gap, while P053T and P016T had received NFV
+3TC+AZT prior to initiation of the program. One child
P016T continued with only a few weeks interruption,
whereas for P053T there was a gap of one year between
his prior ART medication and ART medication provided
through this program. Throughout the study period,
standard treatment was modified in five children
(P007T, P011T, P019T, P031T and P057T). In these chil-
dren, one component of their ART regimen was substi-
tuted respectively: AZT was replaced by stavudine (d4T)
in P011T and P031T, 3TC was replaced by didanosine
(DDI) in P057T, and NFV was replaced by nevirapine
(NVP) in P007T and P019T.Table 1 Basic Characteristics of Study Participants
All
n = 46
Gender (male n) 27
Age (years) 5.6 (0.2;14)
Weight below WHO child reference (n) [33] 43
Weight median z-score (range) −2.0 (−4; 0)
Baseline viral load (RNA/ml) 1.7e5 (2.1e3;1.2e6)
CD4 count (cells/μL) 232 (1; 1519)
Tubercoulosis coinfection (n) 8
Clinical CDC stage
N (not symptomatic) 7
A (mildly symptomatic) 4
B (moderately symptomatic) 15
C (severely symptomatic) 20
Immunological CDC stage
1 4
2 11
3 31
Table 1: Demographic characteristics and baseline disease status of study participanViral dynamics and virologic failure rates
The central tendency of viral dynamics is shown in
Figure 1A. The corresponding viral load measurements
for all children are displayed in Additional File 1. Virologic
failure was defined by two or more measurements demon-
strating > 400 copies/ml RNA after 16 weeks of treatment
(see filled squares in Additional file 1). The cumulative
probability of virologic failure is shown in Figure 1B.
As can be seen, 44% of children experienced virologic
failure during the first year of ART, half of the children
failed before the end of the second year of ART. By the end
of the study, 60 ± 16% had experienced virologic failure.
Both patients who had been infected by blood transfu-
sion (2/2) and all children with previous ART exposure
(4/4) eventually experienced viral failure. None of the 7
children whose mothers had received pMTCT prophylaxis
with AZT +/− NVP (0/7) and none of the children who
had received post-natal AZT prophylaxis for pMTCT (0/3)
experienced virologic failure.
Children who were younger at entry were slightly more
likely to fail ART (p = 0.06 by Wilcoxon rank sum test).
Virologic failure was significantly associated with the im-
munologic CDC-score at baseline (i.e. when starting struc-
tured ART; p < 0.001 by cross-tab χ2 test), with severely
immunosuppressed patients being most likely to fail ART.
In contrast, the CDC clinical category at baseline was
not predictive of virologic failure during subsequent ART.
Children who had reported missing >50% of doses (accord-
ing to the adherence questionnaire administered) were alsoWith subseq. virol. failure Without subseq. virol. failure
n = 26 n = 20
16 11
5.0 (0.67; 13.9) 6.5 (0.7; 13.8)
24 19
−2.5 (−4; 0) −1 (−4; 1)
2.1e5 (2.4e4; 1.1e6) 8.4e5 (2.1e3; 1.2e6)
154 (1; 1591) 381 (2; 870)
3 5
5 2
3 1
7 8
11 9
1 3
1 10
24 7
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growth
Neither immunologic CDC classification, nor clinical
CDC classification at enrolment were correlated with the
age of the children (but with the time between infection
and start of therapy, p = 0.39 and p = 0.83; test for non-
zero correlation).
Study participants were classified in terms of CDC clin-
ical and immune categories at enrolment, during year 1,
during year 2, and after year 2, as shown in Figures 2A-D.
It can be seen in Figure 2A that at the time of enrol-
ment, that the majority of study participants are clustered
in the lower right corner (intensity of shading & percen-
tages shown in the respective fields), which represents im-
munologic suppression (high immunologic CDC scores)
and numerous opportunistic infections (immunologic
scores ‘B’ & ‘C’). During year 1 after the onset of treatment
(Figure 2B) the study participants’ scores are distributed
almost equally throughout the space defined by the re-
spective CDC clinical and immunologic classifiers. During
year 2 after treatment initiation, most of the study partici-
pants showed evidence of immunologic recovery and an
overall decrease in the number of clinical signs of HIV/
AIDS, such as opportunistic infections (increasing percen-
tages are found in the upper left corner in Figure 2C).
After year two, a higher percentage of subjects are repre-
sented in the upper left corner of Figure 2D, while at theDays after treatment initiation
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Figure 1 Viral Load Dynamics and Probability of Virologic Failure. A:
The solid blue squares indicate the median viral load for all patients togeth
(grey shading). The numbers at the top of the figure, e.g. N = 30, indicate t
viral load and its confidence area for the respective time points. B: Kaplan-
treatment initiation.same time there is a slight regression to the right, indicat-
ing an overall clinical deterioration.
The overall rate of clinical/immunologic disease progres-
sion per treatment year is shown in Figures 3B-D: for the
first year after enrolment (panel B), for the second year after
enrolment (panel C), and for the time thereafter (panel D).
It can be seen that antiviral treatment had a very positive
effect on both immunologic and clinical parameters during
the first year after ART initiation as well as during the sub-
sequent year (the blue arrow pointing towards the upper-
left in Figures 3B and C). The rate of improvement was
−0.4 immunologic stages and −0.77 clinical stages during
the first year after treatment initiation and −0.65 immuno-
logic and −0.61 clinical stages from year 1 to year 2.
Immunologic improvement was minimal during year
three (−0.1 stages), whereas the clinical status of the study
participants worsened slightly by 0.16 stages on average
(the blue arrow pointing towards the upper-right in
Figure 3D). The overall changes during year three are very
small. Whether these minor changes are also observable
in larger cohorts, or whether they indicate a stabilization
of immunologic and clinical progression warrants further
investigation.
The immunologic CDC-scores at the time of final assess-
ment were significantly correlated with virologic failure
(p<0.01; cross-tab χ2 test), with patients failing therapy
showing higher scores (i.e. being more severely compro-
mised immunologically), while the final clinical CDC-
scores were not linked.
In summary, immunologic improvement became evi-
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http://www.biomedcentral.com/1471-2334/13/1in this cohort of first-line ART recipients, whereas the cli-
nical improvement (with respect to CDC scores) seemed
to lag behind, possibly due to the fairly advanced disease
stages at baseline.
The median weight after 1, 2 and 3 years of treatment
was 20 kg, 22.3 kg and 23 kg, respectively. The median z-
score was −1. During the first year of ART, 72% of the
children showed negative z-scores, 75% in year 2 and 67%
in/after year 3, which is a considerable improvement over
child weight at enrolment, 93% showed negative z-scores.
Drug resistance testing
On average, drug resistance testing was performed at
2.4 years after the initiation of structured ART. Prior to
the cross-sectional analysis of this treatment cohort, drug
resistance information had not been available to direct the
choice of treatment regimens. In ART-failing patients, the
vast majority of drug resistance tests (96%) were per-
formed at time points after virologic failure.
Samples for RNA consensus sequencing were trans-
ported as dried blood spots on Guthrie cards. RNA ampli-
fication for consensus genotyping was possible in 14/46
samples (including 3 samples with a viral load slightly
below 400 cp/ml), in 4 instances only the protease gene
(PR) could be sequenced. All RNA consensus sequencing
data is provided in Additional file 2. Overall, 70% of HIV-1
RNA sequences were derived from individuals eventually
failing ART. In the remaining cases, RNA could be ampli-
fied from two patients whose viral load had just dropped
below 400cp/ml, one had repeated measurements slightly
below the threshold.
Samples for DNA and RNA OLA testing were trans-
ported as frozen plasma and PBMC samples after Ficoll-
Hypaque centrifugation and separation. Of these, RNA-
OLA testing was performed successfully in 20/46 (43%),
in one case only the protease mutations could be tested by
RNA-OLA. All OLA data is provided in Additional File 3.
As expected, the majority of samples yielding RNA-OLA
results (80%) were derived from patients with detectable
viral loads. DNA-OLA testing however was successful in
almost all patient samples (45/46, 98%), of which 47%
showed no evidence of virologic failure at the time of test-
ing. Hence, DNA-OLA from frozen PBMC provided a sen-
sitive tool for the cross-sectional assessment of archived
drug resistance in this patient cohort. RNA consensus
genotyping from dot blots and RNA-OLA from plasma vi-
rions yielded results predominantly in individuals with
already established virologic failure (over-representing
those with viral loads above the 400cp/ml threshold).
Drug resistance mutations
The M184V reverse transcriptase mutation was detected
in 80% of the sequenced RNA samples and tested positive
in 74% and 47% by RNA-OLA and DNA-OLA, whereasthymidine associated mutations (TAMs: M41L, D67N,
K70R, L210W, T215F/Y, K219Q/E [34]) were detected in
50% of sequenced viral RNA. Using RNA-OLA and DNA-
OLA, the T215Y and T215F mutations tested positive in
47% and 42%, respectively.
The protease mutation D30N was detected in 43% of
RNA genotyping samples and in 0% and 2% of available
RNA- and DNA-OLA samples. The N88D and L90M pro-
tease mutations were detected in 36% and 21% of geno-
typing samples, in 25% and 20% of RNA-OLA samples,
and in 42% and 44% of DNA-OLAs, respectively.
Children who were previously exposed to short-term
antivirals showed significantly higher numbers of resistance
mutations detected by DNA-OLA (p = 0.01 by Wilcoxon
rank sum (WRS) test), but not by RNA-OLA (p = 0.26;
WRS test) or genotyping (p = 0.18; WRS test) at the time
of cross-sectional analysis. Virologic failure was strongly
associated with the number of resistance mutations
detected by DNA-OLA (p < 0.001; WRS test).
The detection of the M184V reverse transcriptase mu-
tation (indicating 3TC resistance) by any of the three
methods (genotyping, RNA-OLA or DNA-OLA) was sig-
nificantly more frequent in patients with virologic failure
(p = 0.07 b, p < 0.05 c and p < 0.001c). Also, the mutations
N88D and L90M (NFV resistance) were more frequently
detected by DNA-OLA in patients with virologic failure
(p < 0.001 and p < 0.05, respectively; WRS test). The pro-
tease mutation D30N was not detected more commonly
in cases of virologic failure (by any of the assays used),
neither were TAMs selected differentially in failing vs.
non-failing patients.
Detection of the M184V, N88D and L90M substitutions
by RNA OLA was highly sensitive for virologic failure
(sensitivity: 0.93, 1.0 and 1.0; binary classification test).
The ability to obtain positive results with the RNA OLA,
along with the detection of mutations M184V, N88D and
L90M, may thus suggest virologic failure in this cohort of
patients.
The detection of the same mutations (M184V, N88D
and L90M) by DNA-OLA yielded a slightly lower sensi-
tivity of 0.86, 0.9 and 0.75 for virologic failure, but the
assay could be performed in almost all patient samples
(regardless of virologic success or failure) indicating that
virologic failure may indeed be attributed to resistance
development at these three residues (these specific mu-
tations appear significantly more frequently in failing
patients, see Table 2).
Relative sensitivities and specificities of the DNA- and
RNA-OLA
We evaluated the DNA-OLA and RNA-OLA relative to
each other in terms of a binary classification test: The
DNA-OLA yielded a sensitivity of 59% relative to the
RNA-OLA. Its relative specificity was 96%. Reversely, the
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http://www.biomedcentral.com/1471-2334/13/1sensitivity of the RNA-OLA relative to the DNA-OLA
was 86%, whereas its specificity was 88%. (Table 3)
Discussion
There are two important aspects in this patient cohort,
characteristic of ART cohorts in resource-limited set-
tings: a) all patients received the same first-line anti-
retroviral regimen and b) patients, on average, were in
advanced stages of HIV/AIDS when starting their first
antiretroviral regimen [35]. When antiretroviral therapy
was first introduced in Peru, uniform criteria were estab-
lished by the MINSA to ensure the allocation of
resources and medication to those most in need. This
first cohort of patients at the largest children’s hospital
in Peru suddenly became eligible for therapy at a time
when many had already progressed to disease stages be-
yond the eligibility threshold.
The effect of delayed access to ART in this first cohort
becomes evident in comparison to a recent study ob-
serving the transmission of resistant virus in a much
younger cohort of neonates and children with timely ac-
cess to pMTCT and ART in Peru, revealing a predomin-
ance of NNRTI mutations, whereas mutations
conferring high-level resistance to ARV were still found
to be rare [18]. This observation is unlikely an effect of
age. Even though our cohort started treatment after the
disease had progressed significantly, age by itself was not
associated with an advanced clinical stage at enrollment.
To the contrary, young age (thus earlier treatment initi-
ation) seemed to favor virologic failure. This may also be
due to a survivor effect, i.e. slower progression in those
patients who had already survived the first years after
MTCT.
Chances of virologic failure were high in this first
pediatric cohort gaining access to ART in Peru in 2002/
3, with ~44% showing virologic failure after the first year
of ART, ~53% after two years. The majority of children
were in poor health, as evidenced by malnutrition 93%
of children below the reference weight for the respective
age group [33]) and a high prevalence of opportunistic
infections. Of note, 43% showed AIDS-defining condi-
tions and 17% co-infections with active tuberculosis. Im-
munologically, 67% of the children had already r.eached
the immunologic CDC category 3 (corresponding to anTable 2 Frequency of Mutations Detected by Different Assays
M184V TAM n Virol. Failure
RNA Genotyping 80%* 50% 10 70%
RNA-OLA 74%** 47%3 19 84%
DNA-OLA 47%*** 42%3 45 53%
Table 2: Frequency of mutations detected by RNA genotyping, RNA-OLA and DNA-O
*associated with virologic failure (p < 0.1),
**strongly associated with virologic failure (p < 0.05),
*** very strong association with virologic failure (p < 0.001).
3 only T215F and T215Y.adult CD4 levels of < 200 cells/μL) prior to gaining ac-
cess to structured ART.
Immunologic classification at baseline was very pre-
dictive for virologic failure. In agreement with studies in
industrialized countries [36,37], these findings indicate
that the percentage of CD4 cells in children with HIV/
AIDS (i.e. the immunologic category) could be used to
guide treatment initiation. In fact, the immunologic clas-
sification may be more valuable for the decision of ART
initiation than relying on DNA-PCR results alone [38].
Despite relatively high rates of virologic failure in this
cohort, both immunological and clinical conditions
improved during ART, in particular throughout the first
and second years of treatment. Thereafter little add-
itional improvement was achieved. Overall, from the
time of initiation of ART up until the time of the cohort
assessment, 57% had showed marked improvement with
respect to their clinical status (as measured by CDC cat-
egory/visit), whereas 35% were unchanged clinically, and
only 8% showed disease progression. With respect to the
immunologic CDC-scores, 76% had improved, 22% had
experienced no change, and 2% showed a decline in
CD4 counts.
For improved visualization of the overall development
of treatment cohorts during ART, we summarized the
clinical and immunological response to therapy in an in-
novative fashion using a Clinical Course Integrated Dis-
play (CCID) with 3-by-4 tables based on the revised
CDC clinical and immunological categories [27]. Here,
we applied the CDC scores as a flexible tool to examine
the cohort on a yearly basis, allowing for CDC scores to
improve or deteriorate, according to the CD4 counts
and reported clinical symptoms. Using this simpleD30N N88D L90M n Virol. Failure
43% 36% 21% 14 70%
0% 25% 20% 20 80%
2% 42%*** 44%** 45 53%
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http://www.biomedcentral.com/1471-2334/13/1system in cross-sectional analyses and surveillance pro-
grams, rates of disease progression (Figure 3) may be
computed for different cohorts allowing the comparison
of treatment strategies in terms of their clinical and im-
munologic effects in a given population. This system may
be applicable to similar cohort studies in developed and
developing countries alike, especially in conjunction with
cross-sectional analyses of antiretroviral drug resistance.
Previous exposure to (often incomplete) ART was signifi-
cantly associated with virologic failure, indicating that short
courses of unsupervised ART prior to the initiation of co-
ordinated long-term treatment programs may be counter-
productive as they may lead to the rapid development of
drug resistance. Archived drug resistance mutations, ac-
quired during previous exposures to antiretrovirals and still
present in the PBMC compartment may be detected reli-
ably by DNA OLA.
Exposure of the newborn to post-natal pMTCT with
AZT did not increase the likelihood of subsequent virolo-
gic failure, neither did maternal exposure to pMTCT with
AZT +/− NVP. There are three possible explanations why
pMTCT did not affect subsequent treatment success:
a) The pMTCT did not lead to a transmission/selection
and “archivation” of drug resistance,
b)Although drug resistance against the pMTCT
regimen (i.e. AZT +/− NVP) developed and was
archived, it did not impede the success of subsequent
triple-drug ART consisting of AZT + 3TC + NFV.
c) Drug resistance did not persist until the initiation of
ART.
In fact, in only one child (P028T) we detected archived
drug resistance by DNA OLA (mutation 215Y; AZT re-
sistance) at the time of cross-sectional resistance testing.
This child (P028T) did not encounter virologic failure
(hinting towards scenario b).
Drug resistance in the context of pMTCT may emerge-
or be transmitted - by two possible mechanisms:
(i) Drug resistant virus is selected in the mother and
passed on to the child (e.g. during birth or
breastfeeding).
(ii) The newborn is infected with susceptible virus and
subsequently selects drug resistant virus, e.g. during
ARV exposure.
Ad (i): When a single dose of antivital medication for
maternal pMTCT is administered at the onset of labor, it
is rather unlikely that drug resistant virus is passed on to
the child. Although the pMTCT regimen may induce a se-
lective pressure on the maternal virus, there is hardly
enough time for this virus to be selected to sufficient
numbers to be transmitted during birth, see also [39].However, drug resistant virus may, with some probability,
be transmitted during subsequent breastfeeding [39].
Newborns P019T, P020T and P028T were not breastfed
and their mothers received a single dose of AZT +/− NVP
shortly before birth. However, these newborns received
6 mg/day (P019T, P020T) or 28 mg/day (P028T) of post-
natal AZT. As explained above, postnatal AZT adminis-
tered to P028T may explain the archiving of AZT resist-
ance in the child’s PBMC DNA (case ii). However, this did
not lead to subsequent therapeutic failure (case b).
The mothers of newborns P002T, P003T, P027T and
P046T were breastfeeding. They received extended AZT
for periods shorter than the actual duration of breastfeed-
ing. None of these children (P002T, P003T, P027T and
P046T) showed evidence of archived AZT resistance
based on DNA-OLA at the time of cross-sectional assess-
ment. These children could have either been infected with
susceptible virus during labour, or during breastfeeding
(after cessation of extended maternal AZT), or else resis-
tance may not have persisted until treatment initiation or
until the DNA OLA was performed.
A potential weakness of a cross-sectional study design is
that clinical and laboratory data from the beginning of
ART up until the date of cross-sectional analysis had to be
extracted from medical records and parent/patient inter-
views. Adherence data using the PACTG questionnaire
are always self-reported. This study design does not allow
for detailed cause-effect analyses, prospective surveillance
and follow-up visits, or the assessment of mortality data.
The cross-sectional analysis however does reflect the real-
world effectiveness of a medical intervention in a low-
resource setting, which often includes patients who would
not typically be able to participate in controlled clinical
trials. The focus of this study was the assessment of the
usefulness of cross-sectional resistance testing using the
DNA versus RNA OLA.
The DNA OLA may be particularly useful for the pur-
poses of population-based surveillance in low resource set-
tings where genotyping tests may not be readily available.
The DNA-OLA was very indicative for the presence of re-
sistance (high specificity, low false positive rate), but less
indicative for the absence of resistance (low sensitivity, high
false negative rate) in comparison to the RNA OLA. To
the contrary, the RNA-OLA was more useful to determine
the absence rather than the presence of drug resistance.
Therefore, DNA-OLA can be used to rule-in resistance,
whereas RNA-OLA may be used to rule-out resistance.
The detection of the resistance mutations M184V,
N88D and L90M by DNA-OLA was highly sensitive for
virologic failure in this cohort treated with lamivudine-
azidothymidine-nelfinavir as first-line therapy. The ana-
lysis of archived HIV-DNA resistance in PBMC provided
useful results in most patients, even if virologic failure was
not (yet) evident. The DNA-OLA may detect resistance
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http://www.biomedcentral.com/1471-2334/13/1mutations that have been acquired during previous expo-
sure to erratic short-term ART, still present in the lym-
phocyte compartment. This may occur in low-resource
settings before antivirals become universally available,
when patients and their families are restricted to tempor-
ary access to limited, often insufficient amounts of anti-
viral medications. Turnover rates within the lymphocyte
compartment may however be too low for the early detec-
tion of antiretroviral drug resistance during therapy (i.e. in
time before viral failure becomes apparent).
A possible strategy for the improvement of ART in
resource-poor settings (where genotyping is often not avail-
able) could be to use the DNA-OLA as a baseline screen-
ing tool before starting therapy. This could be combined
with the use of RNA-OLA in those patients experiencing
virologic failure. Notably, a positive RNA OLA at posi-
tions M184V, N88D or L80M was highly sensitive for vi-
rologic failure (sensitivity: 0.93, 1.0 and 1.0, respectively).
Therefore, drug resistance monitoring at key residues
using RNA OLA in patients experiencing virologic failure
may be particularly useful as an economical indicator of
drug resistance and could suggest a treatment change.
Success rates could likely be improved even further if
treatment was initiated at higher CD4 counts, in line with
recent revisions of the treatment guidelines in industria-
lized countries (initiation of treatment at an adult CD4
count of 350 cell/μL) [36,37]. This is in agreement with re-
cent reports from other cohorts in Latin America. A re-
cent cross-sectional analysis and evaluation of clinical
outcomes of ART in Latin America showed that nearly
half of the patients were so-called “late testers/presenters”.
Evaluations of outcomes with ART in Latin American
children revealed a higher incidence of opportunistic
infections when compared to US cohorts (such as PACTG
129C) [36,37].
While consensus RNA genotyping (if available) will
likely remain the mainstay of individualized resistance
testing during ongoing antiretroviral therapy, the appli-
cability of the OLA in population-based surveillance re-
mains to be fully assessed in larger cohorts, including
cost-effectiveness analyses and assessments of the per-
sonnel and training required for either method. At the
time of the study, genotyping was not available. In recent
years, capacities for monitoring drug resistance have been
expanded at the Peruvian INS including sequencing faci-
lities and an e-health driven, web-based laboratory infor-
mation system [40,41]. The national ART program was
expanded in 2004 to include larger parts of the population
living with HIV/AIDS, including infants in earlier stages
of HIV infection [41-43].
Our data emphasize the need for timely antiretroviral
treatment initiation and early HIV testing to contribute to
this aim [5,12,35,44]. For children undergoing therapy,
regular follow-up visits with viral load and resistance testingand concrete measures to monitor and improve adherence
(using PDA’s, cellphone reminders and other e-health fea-
tures) may be a key to success of ART in Latin America
and beyond [45-52].
Conclusions
1. HIV drug resistance was the major factor
contributing to virologic failure of antiretroviral
therapy in this cohort of children with delayed access
to structured ART in Lima, Peru.
2. In most instances, virologic failure occurred early in
the course of treatment and commonly after previous
exposure to unsupervised ART, but not in relation to
pMTCT.
3. The DNA OLA method detected antiretroviral
resistance at key positions independently of virologic
failure in the form of integrated DNA (in PBMC),
whereas the RNA OLA detected antiviral resistance
in viral RNA (in plasma) only after virologic failure.
Antiviral resistance was more readily detected by
OLA than by RNA consensus genotyping (from dried
blood spots).
4. The DNA-OLA could be used prior to treatment
initiation to rule-out archived drug resistance to
standard regimens, in particular when previous
exposure to antiretrovirals is anticipated. The RNA-
OLA could be used to guide the choice of second-
line antiretrovirals in patients switching ART
regimens after experiencing virologic failure.
Endnotes
a confirmed by DNA-PCR/viral load at 6 months, or
by ELISA at/after 18 months or AIDS-defining diagnosis
b Fisher’s exact test
c χ2 test
Additional files
Additional file 1: Individual viral load dynamics in children after
treatment initiation, stratified by responders (black solid dots) and
children who experienced virologic failure (red squares).
Additional file 2: Sequencing Data. Table with the raw viral
sequencing data from dried blood spots.
Additional file 3 OLA Data. Table with the raw OLA data from
plasma (RNA-OLA) and PBMCs (DNA-OLA).
Abbreviations
INS: Instituto Nacional del Salud (Peruvian National Institutes of Health);
IESN: Instituto Especializado de Salud del Niño; PRISMA: Asociación Benéfica
Proyectos en Informática, Salud, Medicina y Agricultura; MINSA: Ministerio de
Salud del Peru; PACTG: Pediatric AIDS Clinical Trials Group; ART: Antiretroviral
Therapy; MTCT: Mother-to-child transmission; pMTCT: Prevention of mother-
to-child transmission; AZT: Azidotymidine; 3TC: Lamivudine (LMV);
NFV: Nelfinavir; NRTI: Nucleoside-analogue Reverse Transcriptase Inhibitors;
NNRTI: Non-nucleoside-analogue Reverse Transcriptase Inhibitors; PI: Protease
Inhibitor; OLA: Oligonucleotide Ligation Assay; PCR: Polymerase Chain
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
Rath et al. BMC Infectious Diseases 2013, 13:1 Page 11 of 12
http://www.biomedcentral.com/1471-2334/13/1Reaction; RNA: Ribonucleic Acid; DNA: Desoxyribonucleic Acid; WHO: World
Health Organization; HIV: Human immunodeficiency virus; AIDS: Acquired
Immunodeficiency Syndrome.
Competing interest
All authors declare no competing interests.
Authors’ contributions
Study concept and design: BAR, RAO, RVD, DKK. Acquisition of data: BAR,
GSC, MEC, LK. Laboratory Analyses: BAR, PC; AMA, JER, DKK. Analysis and
interpretation of data: MVK, BAR. Drafting of the manuscript: BAR, MVK.
Critical revision of the manuscript for intellectual content: DKK, RAO, RVD,
AMA, GSC, PC. Statistical analysis: MVK. All authors read and approved the
manuscript.
Acknowledgements
The authors kindly thank the staff of the non-governmental organization P.R.
I.S.M.A in Lima, Peru, for their help with the data entry and the abstraction of
medical records, as well as with the preparation, shipping and handling of
blood samples. They thank Prof. Robert Gilman, Johns Hopkins University/
Bloomberg School of Public Health, the INS and the INSN for
accommodating and supporting the study project in Lima. They also thank
Nedra Lacour for the viral load measurements and RNA extraction at the
Tulane PACTU laboratory and Prof. Lisa Frenkel, University of Washington, for
her advice with respect to the OLA testing. All authors declare no
competing interests.
Funding
The authors have no conflicts of interest to declare. This pro bono project
was sponsored by the Department of Pediatrics, Division of Infectious
Diseases at Tulane University Health Sciences Center in New Orleans,
Louisiana. The OLA PRC Primers and Protocol (open-source) provided by the
US National Institutes of Health. Max von Kleist acknowledges funding from
the DFG research center MATHEON provided through project A21
“Modeling, Simulation and Therapy Optimization for Infectious Diseases”.
Author details
1Department of Pediatrics, Division of Pneumonology-Immunology, Charité
University Medical Center, Berlin, Germany. 2Department of Pediatrics,
Division of Infectious Diseases, Tulane University Health Sciences Center,
New Orleans, Louisiana, USA. 3Department of Mathematics and Computer
Science, Free University Berlin, Berlin, Germany. 4Infectious Diseases Service,
Instituto Nacional de Salud del Niño, Principal Professor of the Medicine
School Universidad Peruana Cayetano Heredia, Lima, Peru. 5Executive
Directorate of Research, National Institute of Health, Lima, Peru. 6Asociación
Benéfica PRISMA, Lima, Peru. 7Department of Microbiology, Immunology &
Parasitology, Louisiana State University Health Sciences Center, New Orleans,
Louisiana, USA. 8Center for AIDS Research, Stanford University, Stanford, Palo
Alto, USA. 9Department of Pediatrics, Universidad Peruana Cayetano Heredia,
Lima, Peru. 10Department of Pediatrics, Division of
Pneumonology-Immunology, Charité University Medical Center,
Augustenburger Platz 1, Berlin 13353, Germany.
Received: 2 June 2012 Accepted: 21 December 2012
Published: 2 January 2013
References
1. UNAIDS: Report on the Global AIDS Epidemic - Executive Summary. Geneva,
Switzerland: UNAIDS - Joint United Nations Programme on HIV/AIDS: Edited
by HIV/AIDS U-JUNPo; 2004:1–22.
2. Hainaut M, Ducarme M, Schandene L, Peltier CA, Marissens D, Zissis G,
Mascart F, Levy J: Age-related immune reconstitution during highly active
antiretroviral therapy in human immunodeficiency virus type 1-infected
children. Pediatr Infect Dis J 2003, 22(1):62–69.
3. Curioso WH, Kepka D, Cabello R, Segura P, Kurth AE: Understanding the
facilitators and barriers of antiretroviral adherence in Peru: a qualitative
study. BMC Public Health 2010, 10:13.
4. Franke MF, Murray MB, Munoz M, Hernandez-Diaz S, Sebastian JL, Atwood S,
Caldas A, Bayona J, Shin SS: Food Insufficiency is a Risk Factor forSuboptimal Antiretroviral Therapy Adherence among HIV-Infected Adults
in Urban Peru. AIDS Behav 2011, 15(7):1483–1489.
5. Franke MF, Munoz M, Finnegan K, Zeladita J, Sebastian JL, Bayona JN, Shin
SS: Validation and abbreviation of an HIV stigma scale in an adult
spanish-speaking population in urban Peru. AIDS Behav 2010,
14(1):189–199.
6. Esteban PM, Thahn TG, Bravo JF, Roca LK, Quispe NM, Montano SM, Zunt JR:
Malnutrition associated with increased risk of peripheral neuropathy in
Peruvian children with HIV infection. J Acquir Immune Defic Syndr 2009,
52(5):656–658.
7. Willig JH, Echevarria J, Westfall AO, Iglesias D, Henostroza G, Seas C,
Mugavero MJ, Allison J, Paz J, Hernandez F, et al: Durability of initial
antiretroviral therapy in a resource-constrained setting and the potential
need for zidovudine weight-based dosing. J Acquir Immune Defic Syndr
2010, 53(2):215–221.
8. Shin S, Munoz M, Zeladita J, Slavin S, Caldas A, Sanchez E, Callacna M, Rojas
C, Arevalo J, Sebastian JL, et al: How does directly observed therapy work?
The mechanisms and impact of a comprehensive directly observed
therapy intervention of highly active antiretroviral therapy in Peru.
Health Soc Care Community 2011, 19(3):261–271.
9. Reynolds NR, Testa MA, Marc LG, Chesney MA, Neidig JL, Smith SR, Vella S,
Robbins GK: Factors influencing medication adherence beliefs and self-
efficacy in persons naive to antiretroviral therapy: a multicenter,
cross-sectional study. AIDS Behav 2004, 8(2):141–150.
10. Pontali E, Feasi M, Toscanini F, Bassetti M, De Gol P, Nuzzolese A, Bassetti D:
Adherence to combination antiretroviral treatment in children.
HIV Clin Trials 2001, 2(6):466–473.
11. Cesar C, Shepherd BE, Krolewiecki AJ, Fink VI, Schechter M, Tuboi SH, Wolff
M, Pape JW, Leger P, Padgett D, et al: Rates and reasons for early change
of first HAART in HIV-1-infected patients in 7 sites throughout the
Caribbean and Latin America. PLoS One 2010, 5(6):e10490.
12. Munoz M, Bayona J, Sanchez E, Arevalo J, Sebastian JL, Arteaga F, Guerra D,
Zeladita J, Espiritu B, Wong M, et al: Matching Social Support to Individual
Needs: A Community-Based Intervention to Improve HIV Treatment
Adherence in a Resource-Poor Setting. AIDS Behav 2011, 15(7):1454–1464.
13. Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, Mirochnick
M, Musoke P, Fleming T: Glenn Fowler M, Mofenson LM et al.: Selection
and fading of resistance mutations in women and infants receiving
nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS
2001, 15(15):1951–1957.
14. Wang ME, Castillo ME, Montano SM, Zunt JR: Immune reconstitution
inflammatory syndrome in human immunodeficiency virus-infected
children in Peru. Pediatr Infect Dis J 2009, 28(10):900–903.
15. MINSA: Aprobación de la directiva. In. Lima, Peru: Ministerio de Salud del
Peru (MINSA): Tratamiento Antiretroviral en los niños infectados por el VIH;
2002.
16. MINSA: Guía Nacional de Manejo del Niño infectado por el VIH.: In. Lima:
Ministerio de Salud del Peru (MINSA); 1999.
17. DIRECTIVA No. 020 - 2003-MINSA/DGSP-DEAIS-V.01: 2003 [http://www.
sgcnnavih.cepesju.org/Normativas/DIRECTIVA_020-2003-MINSA_DGSP-
DEAIS-V.01.pdf].
18. Soria J, Bull M, Mitchell C, Rosa AL, Dross S, Kraft K, Coombs R, Ticona E,
Frenkel L: Transmitted HIV Resistance to First-Line Antiretroviral Therapy
in Lima. AIDS Res Hum Retroviruses 2012, 28(4):333–8.
19. Ellis GM, Mahalanabis M, Beck IA, Pepper G, Wright A, Hamilton S, Holte S,
Naugler WE, Pawluk DM, Li CC, et al: Comparison of oligonucleotide
ligation assay and consensus sequencing for detection of drug-resistant
mutants of human immunodeficiency virus type 1 in peripheral blood
mononuclear cells and plasma. J Clin Microbiol 2004, 42(8):3670–3674.
20. Schinazi RF, Schlueter-Wirtz S, Stuyver L: Early detection of mixed
mutations selected by antiretroviral agents in HIV-infected primary
human lymphocytes. Antivir Chem Chemother 2001, 12(Suppl 1):61–65.
21. Frenkel LM, Wagner LE 2nd, Atwood SM, Cummins TJ, Dewhurst S: Specific,
sensitive, and rapid assay for human immunodeficiency virus type 1 pol
mutations associated with resistance to, and didanosine. J Clin Microbiol
1995, 33(2):342–347.
22. Cassol SA, Read S, Weniger BG, Pilon R, Leung B, Mo T: Diagnosis and
Direct Automated Sequencing of HIV-1 From Dried Blood Spots (DBS)
Collected on Filter Paper. Methods Mol Med 1999, 17:125–138.
23. Sherman GG, Stevens G, Jones SA, Horsfield P, Stevens WS: Dried blood
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
Rath et al. BMC Infectious Diseases 2013, 13:1 Page 12 of 12
http://www.biomedcentral.com/1471-2334/13/1spots improve access to HIV diagnosis and care for infants in low-
resource settings. J Acquir Immune Defic Syndr 2005, 38(5):615–617.
24. Youngpairoj AS, Masciotra S, Garrido C, Zahonero N, de Mendoza C, Garcia-
Lerma JG: HIV-1 drug resistance genotyping from dried blood spots stored
for 1 year at 4 degrees C. J Antimicrob Chemother 2008, 61(6):1217–1220.
25. Mitchell C, Jennings C, Brambilla D, Aldrovandi G, Amedee AM, Beck I,
Bremer JW, Coombs R, Decker D, Fiscus S, et al: Diminished human
immunodeficiency virus type 1 DNA yield from dried blood spots after
storage in a humid incubator at 37 degrees C compared to −20 degrees
C. J Clin Microbiol 2008, 46(9):2945–2949.
26. Mitchell C, Kraft K, Peterson D, Frenkel L: Cross-contamination during
processing of dried blood spots used for rapid diagnosis of HIV-1 infection
of infants is rare and avoidable. J Virol Methods 2010, 163(2):489–491.
27. CDC: Revised Classification System for Human Immunodeficiency Virus
Infection in Children Less Than 13 Years of Age. MMWR 1994, 43(12):1–10.
28. Farley JJ, Montepiedra G, Storm D, Sirois PA, Malee K, Garvie P, Kammerer B,
Naar-King S, Nichols S: Assessment of adherence to antiretroviral therapy
in perinatally HIV-infected children and youth using self-report measures
and pill count. J Dev Behav Pediatr 2008, 29(5):377–384.
29. Naar-King S, Montepiedra G, Nichols S, Farley J, Garvie PA, Kammerer B,
Malee K, Sirois PA, Storm D: Allocation of family responsibility for illness
management in pediatric HIV. J Pediatr Psychol 2009, 34(2):187–194.
30. Henning TR, Lacour N, Amedee AM: Efficient methodologies for sensitive
HIV-1 RNA quantitation from plasma and vaginal secretions. J Clin Virol
2009, 46(4):309–313.
31. Beck IA, Mahalanabis M, Pepper G, Wright A, Hamilton S, Langston E,
Frenkel LM: Rapid and sensitive oligonucleotide ligation assay for
detection of mutations in human immunodeficiency virus type 1
associated with high-level resistance to protease inhibitors. J Clin
Microbiol 2002, 40(4):1413–1419.
32. Shafer RW, Hertogs K, Zolopa AR, Warford A, Bloor S, Betts BJ, Merigan TC,
Harrigan R, Larder BA: High degree of interlaboratory reproducibility of
human immunodeficiency virus type 1 protease and reverse transcriptase
sequencing of plasma samples from heavily treated patients. J Clin Microbiol
2001, 39(4):1522–1529.
33. Child Growth Standards: [http://www.who.int/childgrowth/standards/
weight_for_age/en/index.html].
34. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer R, Wensing
AM, Richman DD: 2011 update of the drug resistance mutations in HIV-1.
Top Antivir Med 2011, 19(4):156–164.
35. Crabtree-Ramirez B, Caro-Vega Y, Shepherd BE, Wehbe F, Cesar C, Cortes C,
Padgett D, Koenig S, Gotuzzo E, Cahn P, et al: Cross-sectional analysis of
late HAART initiation in Latin America and the Caribbean: late testers
and late presenters. PLoS One 2011, 6(5):e20272.
36. Alarcon JO, Freimanis-Hance L, Krauss M, Reyes MF, Cardoso CA, Mussi-Pinhata
MM, Cardoso E, Alarcon JO, Freimanis-Hance L, Krauss M, Reyes MF, Cardoso
CA, Mussi-Pinhata MM, Cardoso E, Alarcon JO, Freimanis-Hance L, Krauss M,
Reyes MF, Cardoso CA, Mussi-Pinhata MM, Cardoso E: Opportunistic and
other infections in HIV-infected Children in Latin America compared to a
similar cohort in the United States. AIDS Res Hum Retroviruses 2012,
28(3):282–8.
37. Patel K, Hernan MA, Williams PL, Seeger JD, McIntosh K, Dyke RB, Seage GR
3rd: Long-term effects of highly active antiretroviral therapy on CD4+
cell evolution among children and adolescents infected with HIV:
5 years and counting. Clin Infect Dis 2008, 46(11):1751–1760.
38. Feucht UD, Forsyth B, Kruger M: False-positive HIV DNA PCR testing of
infants: Implications in a changing epidemic. S Afr Med J 2012,
102(3):149–152.
39. Frank M, von Kleist M, Kunz A, Harms G, Schutte C, Kloft C: Quantifying the
impact of nevirapine-based prophylaxis strategies to prevent mother-to-
child transmission of HIV-1: a combined pharmacokinetic,
pharmacodynamic, and viral dynamic analysis to predict clinical
outcomes. Antimicrobial agents and chemotherapy 2011, 55(12):5529–5540.
40. Garcia PJ, Vargas JH, Caballero NP, Calle VJ, Bayer AM: An e-health driven
laboratory information system to support HIV treatment in Peru: E-quity
for laboratory personnel, health providers and people living with HIV.
BMC Med Inform Decis Mak 2009, 9:50.
41. MINSA: A Step Forward in the FIght Against AIDS. In. Lima: Ministerio de
Salud del Peru (MINSA): The first two years of universal access to
antiretroviral treatment in Peru; 2006.42. Aldridge RW, Iglesias D, Caceres CF, Miranda JJ: Determining a cost
effective intervention response to HIV/AIDS in Peru. BMC Public Health
2009, 9:352.
43. Tuboi SH, Schechter M, McGowan CC, Cesar C, Krolewiecki A, Cahn P, Wolff
M, Pape JW, Padgett D, Madero JS, et al: Mortality during the first year of
potent antiretroviral therapy in HIV-1-infected patients in 7 sites
throughout Latin America and the Caribbean. J Acquir Immune Defic Syndr
2009, 51(5):615–623.
44. Clark JL, Long CM, Giron JM, Cuadros JA, Caceres CF, Coates TJ, Klausner JD:
Partner notification for sexually transmitted diseases in Peru: knowledge,
attitudes, and practices in a high-risk community. Sex Transm Dis 2007,
34(5):309–313.
45. Furin JJ, Behforouz HL, Shin SS, Mukherjee JS, Bayona J, Farmer PE, Kim JY,
Keshavjee S: Expanding global HIV treatment: case studies from the field.
Ann N Y Acad Sci 2008, 1136:12–20.
46. Curioso WH, Kurth AE: Access, use and perceptions regarding Internet,
cell phones and PDAs as a means for health promotion for people living
with HIV in Peru. BMC Med Inform Decis Mak 2007, 7:24.
47. Bastos FI, Caceres C, Galvao J, Veras MA, Castilho EA: AIDS in Latin America:
assessing the current status of the epidemic and the ongoing response.
Int J Epidemiol 2008, 37(4):729–737.
48. Curioso WH, Kurth AE, Cabello R, Segura P, Berry DL: Usability evaluation of
Personal Digital Assistants (PDAs) to support HIV treatment adherence
and safer sex behavior in Peru. AMIA Annu Symp Proc 2008, 918.
49. Kurth AE, Curioso WH, Ngugi E, McClelland L, Segura P, Cabello R, Berry DL:
Personal digital assistants for HIV treatment adherence, safer sex
behavior support, and provider training in resource-constrained settings.
AMIA Annu Symp Proc 2007, 1018.
50. Lopez De Castilla D, Verdonck K, Otero L, Iglesias D, Echevarria J, Lut L,
Gotuzzo E, Seas C: Predictors of CD4+ cell count response and of adverse
outcome among HIV-infected patients receiving highly active
antiretroviral therapy in a public hospital in Peru. Int J Infect Dis 2008,
12(3):325–331.
51. Corey DM, Kim HW, Salazar R, Illescas R, Villena J, Gutierrez L, Sanchez J, Tabet
SR: Brief report: effectiveness of combination antiretroviral therapy on
survival and opportunistic infections in a developing world setting: an
observational cohort study. J Acquir Immune Defic Syndr 2007, 44(4):451–455.
52. Cohen J: HIV/AIDS: Latin America & Caribbean. Peru: universal access:
more goal than reality. Science 2006, 313(5786):489.
doi:10.1186/1471-2334-13-1
Cite this article as: Rath et al.: Antiviral Resistance and Correlates of
Virologic Failure in the first Cohort of HIV-Infected Children Gaining
Access to Structured Antiretroviral Therapy in Lima, Peru: A Cross-
Sectional Analysis. BMC Infectious Diseases 2013 13:1.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
